On Wednesday, an SEC filing was revealed regarding the insider transaction of Protalix Bio Therapeutics Inc. (PLX) stock. The company’s CEO acquired some shares of
In the regular trading session on April 4, 2022, Protalix Bio Therapeutics Inc. (PLX) stock saw an upsurge of 41.90%. Trending at a hefty volume
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.